Invention Grant
- Patent Title: Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
-
Application No.: US16487330Application Date: 2018-01-05
-
Publication No.: US11319372B2Publication Date: 2022-05-03
- Inventor: Frank J Calzone , Hai Yan
- Applicant: REMD Biotherapeutics, Inc.
- Applicant Address: US CA Camarillo
- Assignee: REMD Biotherapeutics, Inc.
- Current Assignee: REMD Biotherapeutics, Inc.
- Current Assignee Address: US CA Camarillo
- Agency: Craig A Crandall, APC
- Agent Craig A Crandall
- International Application: PCT/US2018/012545 WO 20180105
- International Announcement: WO2018/156250 WO 20180830
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C07K16/00 ; C07H21/04 ; C12N1/20 ; C12N15/00 ; C12N5/20 ; C07K16/28 ; A61P35/00
Abstract:
This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting CTLA-4 expressed on injured tissues associated with multiple diseases. These anti-CTLA-4 antibodies, or antigen-binding fragments thereof, have a high affinity for CTLA-4 and function to inhibit CTLA-4. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.
Public/Granted literature
- US20200055937A1 CANCER TREATMENT USING ANTIBODIES THAT BIND CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 (CTLA-4) Public/Granted day:2020-02-20
Information query
